Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.50 |
| ▸ | SELP | P16109 | 1/20 | 0.47 |
| ▸ | P2RY10 | O00398 | 7/20 | 0.47 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.45 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9286668 | 1.00 | USP2 (0.54) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL10664178 | 0.98 | USP2 (0.57) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL28659331 | 0.98 | USP2 (0.57) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL30888163 | 0.98 | USP2 (0.57) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL17528452 | 0.98 | USP2 (0.57) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL23016732 | 0.98 | USP2 (0.57) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL27597717 | 0.95 | LPAR5 (0.47) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| Glycerin SCHEMBL31314372 | 0.90 | LPAR3 (0.58) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL17528484 | 0.90 | USP2 (0.59) | USP2LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL18721639 | 0.88 | LPAR5 (0.46) | USP2LPAR5LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010007865-A1 | Prodrugs with enhanced penetration into cells | D-PHARM LTD. (IL) | 2001-07-12 | — | — | US | claimed |
| US-6077837-A | ADMINISTERING PRODRUG TO MAMMAL COMPRISING PROTEIN KINASE INHIBITOR COVALENTLY BONDED TO TRANSPORTING ADJUVANT, THE COVALENT BOND BEING CLEAVED IN PRESENCE OF SUPERNORMAL ENZYME ACTIVITY TO TREAT CONDITIONS LIKE STROKE, EPILEPSY, ASTHMA | D-PHARM LTD. (IL) | 2000-06-20 | — | — | US | claimed |
| EP-0691852-A1 | PRODRUGS WITH ENHANCED PENETRATION INTO CELLS | D-PHARM, LTD. (IL) | 1996-01-17 | — | — | EP | claimed |
| WO-1994022483-A2 | PRODRUGS WITH ENHANCED PENETRATION INTO CELLS | D-PHARM, LTD. (IL) | 1994-10-13 | — | — | WO | claimed |
| WO-2024079137-A1 | INCREASING LEAF BIOMASS AND NITROGEN USE EFFICIENCY BY REGULATING NTP2 | PHILIP MORRIS PRODUCTS S.A. (CH) | 2024-04-18 | — | — | WO | disclosed |
| EP-3169149-B1 | TOBACCO PROTEASE GENES | PHILIP MORRIS PRODUCTS SA (CH) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023117701-A1 | MODULATION OF NICOTINE PRODUCTION BY ALTERATION OF NICOTINAMIDASE EXPRESSION OR FUNCTION IN PLANTS | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023117661-A1 | INCREASING ANATABINE IN TOBACCO LEAF BY REGULATING METHYL PUTRESCINE OXIDASE | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-06-29 | — | — | WO | disclosed |
| US-20230200344-A1 | MODULATING SUGAR AND AMINO ACID CONTENT IN A PLANT (SULTR3) | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-06-29 | — | — | US | disclosed |
| US-11685929-B2 | Plants with shortened time to flowering | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-06-27 | — | — | US | disclosed |
| US-11591609-B2 | Modulating reducing sugar content in a plant | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-02-28 | — | — | US | disclosed |
| EP-4041753-A1 | MODULATING SUGAR AND AMINO ACID CONTENT IN A PLANT (SULTR3) | Philip Morris Products S.A. (CH) | 2022-08-17 | — | — | EP | disclosed |
| EP-2565271-A1 | Threonine synthase from Nicotiana tabacum and methods and uses thereof | Philip Morris Products S.A. (CH) | 2013-03-06 | — | — | EP | disclosed |
| CN-101432427-B | Method for identifying useful protein derived from brewery yeast | SUNTORY LTD | 2012-05-09 | — | — | CN | disclosed |
| WO-2012028309-A2 | HEAVY METAL REDUCTION IN PLANTA | PHILIP MORRIS PRODUCTS S.A. (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011127069-A1 | MODIFIED PHOTOSYNTHETIC MICROORGANISMS FOR PRODUCING LIPIDS | TARGETED GROWTH, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20110250659-A1 | MODIFIED PHOTOSYNTHETIC MICROORGANISMS FOR PRODUCING LIPIDS | TARGETED GROWTH, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| CN-101432427-A | Method for identifying useful proteins of brewery yeast | SUNTORY LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| WO-1989004314-A1 | ANTI-VIRAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM | SCIENSCOPE INTERNATIONAL, N.V. (AN) | 1989-05-18 | — | — | WO | disclosed |
| EP-0316117-A1 | Antiviral compounds, compositions containing such compounds and methods of treatment | SCIENSCOPE INTERNATIONAL N.V. (AN) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007865-A1 | Prodrugs with enhanced penetration into cells | SLC5A7, MMP1, DNPEP | USP2 2496/4885LPAR5 1332/4885LPAR3 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.